STAT3 and liver cancer: Raloxifene is a suitable agent for targeting liver cancer and possibly certain type of cancer cells with constitutively activated STAT3 induced by IL-6, due to its ability to inhibit IL-6/GP130 binding as well as their potent growth suppressive activity both in vitro and in vivo.